Fashion brands Lilly Pulitzer and Dee Ocleppo have collaborated on a limited-edition capsule collection. The collection is described as a "love letter to Palm Beach" and features two new prints. Dee ...

Nov 13 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab denied weight-loss drug partnership with Mangoceuticals (MGRX.O), opens new tab on Thursday, hours after ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies to provide direct access to their popular obesity meds. Thursday morning, ...

PALM BEACH, Fla., Nov. 13, 2025 /PRNewswire/ -- Sunshine, sparkle, and style collide as powerhouse entrepreneur Dee Ocleppo Hilfiger joins forces with legendary resortwear brand Lilly Pulitzer to ...

Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using artificial intelligence to discover new drugs. The Indianapolis Big Pharma will combine Insilico’s Pharma ...

The Lilly Pulitzer flagship store on Worth Avenue in Palm Beach has reopened after a significant interior remodel. Renovations include a more open floor plan, updated dressing rooms and a new custom ...

During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma companies in building out its U.S. supply chain. Now, after making several major ...

Patients will be able to access Eli Lilly's weight loss drug Zepbound at Walmart pharmacies nationwide through its direct-to-consumer program as soon as next month. The partnership between Eli Lilly ...

The Evangeline Aquifer project could threaten Sinton’s water supply, prompting growing concern among city leaders and residents. Prince Andrew stripped of titles and must surrender lease to Windsor ...

Kicking off the summer, Eric Church released his first album in four years with Evangeline vs. the Machine. While featuring songs like “Johnny” and “Hands of Time”, the album nabbed the No. 1 spot on ...

Changes are expected to reduce future study costs, accelerate objective readouts, and extend operating runway under current plans SEATTLE, Oct. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc.